Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Jul 12, 2026
Strategy Inc. (MSTR): Is $500 Within Reach?

Strategy Inc. (MSTR): Is $500 Within Reach?

Key Takeaways

  • Strategy Inc. (NASDAQ: MSTR), formerly MicroStrategy, currently trades below the $100 level, making a move to $500 a potential gain of more than 400% from mid-2026 levels.
  • The single most important driver for any sustained rally toward $500 is a major recovery in Bitcoin, given that Strategy holds over 713,000 BTC on its balance sheet.
  • Wall Street analyst price targets span a wide range from $175 to $705, with a consensus average near $375–$500, reflecting widely divergent Bitcoin price assumptions.
  • The biggest obstacle remains persistent shareholder dilution from ongoing capital-raising activities, which can erode per-share value even if Bitcoin appreciates.
  • Technical analysis identifies the $100 level as critical resistance that must be reclaimed before any credible move toward $200, and eventually $500, can develop.
  • Reaching $500 is plausible under a strong Bitcoin bull scenario with disciplined capital allocation, but the path depends heavily on cryptocurrency market conditions and management's financing decisions.

Why the $500 Level Matters

The $500 price target for Strategy (MSTR) stock has become a focal point in market discussions, appearing in analyst reports, financial media, and investor forums. This round-number psychological level sits near the center of Wall Street's target range, with firms such as Mizuho ($484), Canaccord Genuity ($474), and HC Wainwright ($475–$521) all publishing targets clustered around the $500 mark in recent quarters. The target also carries significance because it would roughly represent a recovery to the levels where MSTR traded before its sharp correction from mid-2025 highs above $450. For investors who watched the stock decline more than 60% from those peaks, $500 represents a tangible recovery milestone rather than an arbitrary number.

Company Overview

Strategy Inc., which rebranded from MicroStrategy Incorporated in August 2025, has transformed from an enterprise analytics software company into the world's largest corporate Bitcoin treasury. Under the leadership of CEO Phong Le and Executive Chairman Michael Saylor, the company has accumulated approximately 713,000 BTC, representing roughly 3.4% of Bitcoin's total circulating supply. The legacy software business continues to generate annual revenue of approximately $477 million with accelerating cloud growth, but it now represents only a fraction of the company's enterprise value. The market overwhelmingly values Strategy based on its Bitcoin holdings and its ability to grow Bitcoin-per-share over time, a metric the company calls BTC Yield.

Current Market Position

As of mid-2026, MSTR stock has endured a punishing drawdown. After rallying above $200 earlier in the year alongside a Bitcoin recovery, the stock corrected sharply and recently fell below the psychologically important $100 level. The former $100 support zone has now flipped to resistance, while the next meaningful demand zone sits near $70–$75. The stock remains below both its 50-day and 200-day moving averages, and a descending trendline continues to cap upside attempts. The decline reflects a combination of Bitcoin price weakness, concerns about ongoing capital-raising dilution, and broader risk-off sentiment in both equity and cryptocurrency markets. With a beta of approximately 3.5 relative to Bitcoin, MSTR has amplified every downward move in the underlying cryptocurrency. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Factors That Could Drive MSTR Toward $500

The path to $500 rests primarily on a sustained Bitcoin bull market. Using the company's holdings and capital structure, a Bitcoin price in the range of $120,000 to $150,000 would place the value of Strategy's BTC treasury at approximately $85 billion to $107 billion. After accounting for net liabilities and applying a reasonable premium for the company's institutional-grade wrapper, per-share values in the $400–$600 range become mathematically achievable. Several analysts, including Benchmark's Mark Palmer with his $705 price target, base their bullish outlooks on precisely this type of Bitcoin scenario.

Beyond Bitcoin price appreciation, disciplined capital allocation would be essential. If management prioritizes Bitcoin purchases when the company's market value relative to its net asset value (mNAV) is favorable and limits dilutive equity issuance during periods of compressed valuations, per-share Bitcoin accumulation can accelerate. The company has demonstrated an ability to raise capital through preferred share offerings rather than solely relying on common stock, which may reduce dilution. Additionally, the software business provides a non-Bitcoin revenue floor and operating cash flow that supports ongoing operations without forced Bitcoin sales.

Key Risks That Could Prevent the Move

The most significant obstacle to reaching $500 is the ongoing dilution from Strategy's capital-raising activities. The company raised approximately $25.3 billion through secondary offerings in 2025 alone, and management has signaled intentions to continue issuing shares indefinitely to fund Bitcoin purchases. At current issuance rates, annual dilution could exceed 10–15%, meaning Bitcoin would need to appreciate substantially just to keep per-share value flat. If capital is raised during periods of low mNAV, existing shareholders experience permanent value destruction.

Bitcoin price risk remains the dominant factor. If Bitcoin fails to sustain a meaningful recovery or enters another prolonged bear market, Strategy's leveraged exposure works against shareholders. A continued decline in Bitcoin toward or below the company's cost basis would trigger unrealized losses and potentially force difficult decisions about asset sales. Regulatory developments affecting cryptocurrency taxation, custody, or corporate treasury treatment could also compress the premium that investors are willing to pay for MSTR relative to its net asset value.

Analyst Opinions and Price Targets

Wall Street maintains a broadly constructive stance on MSTR, with 13 of 14 analysts rating the stock as Buy or Strong Buy as of the latest available coverage. However, price targets vary dramatically, reflecting fundamentally different Bitcoin price assumptions. The most bullish targets include Benchmark at $705 and BTIG at $630, while more cautious firms such as B. Riley Securities maintain targets around $175. The consensus average across all analysts sits near $375–$500, with Citigroup at $325, Bernstein at $450, and firms like Canaccord Genuity and HC Wainwright clustered in the $474–$521 range. One notable dissenter, Monness, Crespi, Hardt, maintained a Sell rating with a $175 target, citing concerns about premium valuation and dilution. The wide dispersion underscores that MSTR price targets are essentially Bitcoin price forecasts expressed through a corporate capital structure lens.

Technical Levels That Matter

From a technical analysis perspective, several levels are critical for any sustained move toward $500. The $100 level represents the most immediate hurdle — it served as important support for months before breaking down and now stands as resistance that must be reclaimed with conviction. Above $100, the next significant resistance zone appears near $120–$135, followed by the $160–$200 area where the stock traded during the first half of 2026. The $200 level carries psychological weight as a round number and coincides with prior consolidation ranges. Beyond $200, the $325–$350 zone represents the next major structural resistance before the $425–$455 region where MSTR peaked in mid-2025. On the downside, support near $70–$75 must hold to prevent a deeper decline toward the 52-week lows.

Additional Risks Investors Should Consider

Beyond Bitcoin price and dilution risk, several additional factors warrant attention. Strategy trades at a premium to its net asset value, meaning investors pay more than the market value of the underlying Bitcoin holdings. If this premium compresses — as it has historically during risk-off periods — the stock can underperform Bitcoin itself. The company's heavy reliance on capital markets means that any disruption to equity or preferred share issuance capacity could constrain the Bitcoin accumulation strategy. Competition from spot Bitcoin ETFs, which offer direct Bitcoin exposure at lower cost, may also limit MSTR's ability to command a sustained premium. Finally, concentration risk is extreme: a single asset class and a single corporate strategy determine virtually all of the company's value.

AI Daily Buy/Sell Signals

Traders navigating the inherent volatility of MSTR can benefit from tools that provide timely, data-driven market insights. Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. These signals are designed to help traders discover new opportunities, monitor existing positions, and identify shifting market trends with greater efficiency than manual scanning allows. For a stock as volatile and news-sensitive as Strategy, having an AI-powered monitoring system can provide an edge in recognizing trend changes before they become obvious to the broader market.

Final Assessment

In my view, the question of whether Strategy stock can reach $500 depends overwhelmingly on Bitcoin's future trajectory and management's capital allocation discipline. Under a scenario where Bitcoin rallies to $120,000–$150,000 and the company finances further accumulation with limited per-share dilution, a $500 price target appears mathematically achievable and consistent with multiple Wall Street models. However, the path from current levels below $100 to $500 requires not only a powerful Bitcoin recovery but also sustained investor confidence in Strategy's premium valuation, manageable dilution rates, and favorable regulatory and macroeconomic conditions. The stock's elevated beta means any Bitcoin rally would likely produce outsized gains, but the inverse is equally true. I'm watching Bitcoin price trends, quarterly filings for share-count changes, and the mNAV premium as the three most important indicators of whether $500 is becoming more or less realistic. While reachable under optimistic conditions, $500 remains a high-conviction target rather than a baseline expectation, and the journey would almost certainly involve substantial volatility along the way.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: MSTR

Contributor

<p>Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years&nbsp;developing&nbsp;his proprietary trading and quantitative algorithms (now Tickeron&rsquo;s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional,&nbsp;sophisticated stock market analysis capabilities to retail investors via&nbsp;an easy-to-use interface.</p>


Momentum Indicator for MSTR turns positive, indicating new upward trend

MSTR saw its Momentum Indicator move above the 0 level on August 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 76 similar instances where the indicator turned positive. In of the 76 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MSTR's RSI Indicator exited the oversold zone, of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for MSTR just turned positive on July 06, 2026. Looking at past instances where MSTR's MACD turned positive, the stock continued to rise in of 36 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MSTR advanced for three days, in of 281 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MSTR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for MSTR entered a downward trend on July 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.205) is normal, around the industry mean (28.085). P/E Ratio (5.299) is within average values for comparable stocks, (80.367). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.677). Dividend Yield (0.000) settles around the average of (0.048) among similar stocks. P/S Ratio (61.350) is also within normal values, averaging (68.964).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. MSTR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MSTR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Shopify Inc (NASDAQ:SHOP), Salesforce (NYSE:CRM), Uber Technologies (NYSE:UBER), ServiceNow Inc. (NYSE:NOW), Adobe (NASDAQ:ADBE), Intuit (NASDAQ:INTU), Datadog (NASDAQ:DDOG), Autodesk (NASDAQ:ADSK), Workday (NASDAQ:WDAY), Zoom Communications Inc (NASDAQ:ZM).

Industry description

Packaged software comprises multiple software programs bundled together and sold as a group. For example, Microsoft Office includes multiple applications such as Excel, Word, and PowerPoint. In some cases, buying a bundled product is cheaper than purchasing each item individually[s20] . Microsoft Corporation, Oracle Corp. and Adobe are some major American packaged software makers.

Market Cap

The average market capitalization across the Packaged Software Industry is 9.77B. The market cap for tickers in the group ranges from 291 to 225.77B. SAP holds the highest valuation in this group at 225.77B. The lowest valued company is BLGI at 291.

High and low price notable news

The average weekly price growth across all stocks in the Packaged Software Industry was 5%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was 3%. YXT experienced the highest price growth at 151%, while NXTT experienced the biggest fall at -86%.

Volume

The average weekly volume growth across all stocks in the Packaged Software Industry was 23%. For the same stocks of the Industry, the average monthly volume growth was 37% and the average quarterly volume growth was -25%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 78
Price Growth Rating: 58
SMR Rating: 78
Profit Risk Rating: 94
Seasonality Score: -4 (-100 ... +100)
View a ticker or compare two or three
MSTR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a provider of e-business software and services

Industry PackagedSoftware

Profile
Details
Industry
Internet Software Or Services
Address
1850 Towers Crescent Plaza
Phone
+1 703 848-8600
Employees
1539
Web
https://www.strategy.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.